Justin L.

Background

About Justin L.

With a 20-year technical and scientific background, I have successfully identified customers and partners, launched molecular diagnostic products, and built business strategies from concept to market. My work has focused on new product initiation, business partnerships, and marketing strategies backed by market research in molecular diagnostics. I have also managed distributors and teams across customer service, product training, marketing, regulatory compliance, and sales forecasting.Currently, I lead Promis Dx’s business operations, overseeing infectious disease and oncology programs, including colorectal cancer (CRC), bladder cancer, and lung cancer. We partnered on pilot clinical studies and advanced preparations for pivotal clinical trials. Our bladder cancer program, EarlyTect® BCD, achieved major milestones:v Gained FDA Breakthrough Device Designation for EarlyTect® BCDv Launched EarlyTect® BCD as the first commercial product v Secured a proprietary CPT PLA code ($192) to support reimbursement.v Recognized EarlyTect® BCD in the 2025 AUA/SUFU Guideline as a validated urinary biomarker.SpecialtiesProduct definition and developmentStrategic planning and market researchPricing, portfolio valuation, and commercial assessmentFDA clinical trials and operationsChannel sales, product positioning, and marketing executionMarketsMolecular diagnostics, oncology, infectious disease, women’s health, point of care, NIPT, next-generation sequencing, digital PCR